학술논문
Updated data from IMPemBra, a phase 2 Study Comparing Pembrolizumab (PEM) with Intermittent/short-term dual MAPK pathway inhibition (MAPKi, dabrafenib plus trametinib, D plus T) plus PEM in patients harboring the BRAFV600 mutation
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
14795876